Which is more effective for treating PTSD: Medication, or psychotherapy?

December 19, 2019

CHAPEL HILL, N.C. (December 19, 2019) - A new study that sought to find out whether serotonin reuptake inhibitors or trauma-focused psychotherapy is more effective in treating posttraumatic stress disorder (PTSD) concluded there is insufficient evidence at present to make that determination.

"Because of these findings, we recommend that, until we have evidence from head-to-head trials favoring one treatment or the other, clinicians should make shared decisions, with patients, about which treatment modality to use," said Jeffrey Sonis, MD, MPH, lead author of the study and an associate professor in the departments of social medicine and family medicine in the University of North Carolina School of Medicine. "These decisions should be based on patient preferences with regard to several treatment characteristics, such as the frequency of visits and time between treatment initiation and the onset of beneficial effects."

The systematic review and meta-analysis was led by Sonis and is published in the December 2019 issue of the journal Psychiatry Research. Joan M. Cook, PhD, of Yale University is co-author of the study.

Most guidelines for the treatment of PTSD in adults recommend that trauma-focused psychotherapy be used as a first-line treatment and medications be used as a second-line treatment, Sonis said. In other words, they recommend that psychotherapy should be offered, preferentially, to adults with PTSD, over medication. Those guidelines base those recommendations upon the fact that the effect sizes (the magnitude of the treatment effects) from randomized trials that compare psychotherapy to controls (such as wait-list controls) are substantially larger than the effect size from trials comparing medications to placebo.

However, comparing effect sizes based on indirect comparison is a flawed approach, Sonis said, because methodological differences between psychotherapy trials and medication trials are known to be associated with the effect size. For instance, blinding or masking, which is routine in medication trials but impossible in psychotherapy trials is known to be associated with smaller effect sizes. Other methodological differences are also associated with effect size and may explain the difference in effect sizes for psychotherapy and medication trials.

"We believe that only head-to-head randomized trials comparing psychotherapy directly to medications should be used to determine the relative effectiveness of psychotherapy and medications for treatment of PTSD," Sonis said. "There have been other meta-analyses of head-to-head randomize trials for treatment of PTSD previously but several head-to-head trials had been published since the last meta-analysis. Therefore, we conducted a meta-analysis exclusively consisting of head-to-head randomized trials."

"We found that the best estimate of the effect, comparing psychotherapy and medications, was that there was no difference between the two. However, the 95% confidence interval was very wide, indicating that true effect may favor psychotherapy or it may favor medications. We concluded that there is still insufficient evidence to determine whether psychotherapy or medications were more effective for treatment of PTSD in adults," Sonis said.

Until there is clear evidence from head-to-head trials favoring one treatment or the other, Sonis said, clinicians should make shared decisions, with patients, about which treatment modality to use, based not on comparative effectiveness (which is inconclusive) but on patient preferences regarding the following factors:"The bottom line is that while many researchers and clinicians believe that psychotherapy is more effective for treatment of PTSD than medications, our research shows that there is -- as of right now -- insufficient evidence from head-to-head trials to make that determination at this time," Sonis said. "Therefore, the choice of medication or psychotherapy as the initial treatment should be based on patient preferences for treatment characteristics and not on incorrect assumptions about which treatment is more effective."

University of North Carolina Health Care

Related PTSD Articles from Brightsurf:

'Brain fog' following COVID-19 recovery may indicate PTSD
A new report suggests that lingering ''brain fog'' and other neurological symptoms after COVID -19 recovery may be due to post-traumatic stress disorder (PTSD), an effect observed in past human coronavirus outbreaks such as SARS and MERS.

PTSD may double risk of dementia
People who have experienced post-traumatic stress disorder (PTSD) are up to twice as likely to develop dementia later in life, according to a new study by UCL researchers, published in the British Journal of Psychiatry.

How building features impact veterans with PTSD
The built environment, where someone lives (private) or works (public), influences a person's daily life and can help, or hinder, their mental health.

Work-related PTSD in nurses
A recent Journal of Clinical Nursing analysis of published studies examined the prevalence of post-traumatic stress disorder (PTSD) among nurses and identified factors associated with work-related PTSD among nurses.

PTSD and moral injury linked to pregnancy complications
Elevated symptoms of PTSD and moral injury can lead to pregnancy complications, found a Veterans Affairs study of women military veterans.

Early treatment for PTSD after a disaster has lasting effects
In 1988, a 6.9 magnitude earthquake struck near the northern Armenian city of Spitak.

Cyberbullying Linked to Increased Depression and PTSD
Cyberbullying had the impact of amplifying symptoms of depression and post-traumatic stress disorder in young people who were inpatients at an adolescent psychiatric hospital, according to a new study published in the Journal of Clinical Psychiatry.

Psychedelic drugs could help treat PTSD
Clinical trials suggest treatment that involves psychedelics can be more effective than psychotherapy alone.

Which is more effective for treating PTSD: Medication, or psychotherapy?
A systematic review and meta-analysis led by Jeffrey Sonis, MD, MPH, of the University of North Carolina School of Medicine, finds there is insufficient evidence at present to answer that question.

Cannabis could help alleviate depression and suicidality among people with PTSD
Cannabis may be helping Canadians cope with the effects of post-traumatic stress disorder (PTSD), new research suggests.

Read More: PTSD News and PTSD Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.